

Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study

Authors

Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D. Bledsoe, Naval G. Daver, Elias J. Jabbour, Tapan M. Kadia, Zeev Estrov, Steven M. Kornblau, Michael Andreeff, Nitin Jain, Jorge E. Cortes,[°] Gautam Borthakur, Yesid Alvarado, Mary Ann Richie, Mackenzie H. Dobbins, Selene A. McCrackin, Lingsha Zhou, Sherry A. Pierce, Xuemei Wang, Allison M. Pike, Guillermo Garcia-Manero, Hagop M. Kantarjian and Srdan Verstovsek[°]

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

[°]SV current address: Kartos Therapeutics, Redwood City, CA, USA

[°]JEC current address: Georgia Cancer Center, Augusta, GA, USA

Correspondence:


P. BOSE - pbose@mdanderson.org

<https://doi.org/10.3324/haematol.2023.284078>

Supplemental Material

Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study

Prithviraj Bose,* Lucia Masarova, Naveen Pemmaraju, Sharon D. Bledsoe, Naval G. Daver, Elias J. Jabbour, Tapan M. Kadia, Zeev Estrov, Steven M. Kornblau, Michael Andreeff, Nitin Jain, Jorge E. Cortes, Gautam Borthakur, Yesid Alvarado, Mary Ann Richie, Mackenzie H. Dobbins, Selene A. McCrackin, Lingsha Zhou, Sherry A. Pierce, Xuemei Wang, Allison M. Pike, Guillermo Garcia-Manero, Hagop M. Kantarjian, Srdan Verstovsek



Supplemental Figure 1. Consort diagram of patient disposition on the trial.

Data on patients that did not sign informed consent were not collected.

Abbreviations: AML: acute myeloid leukemia; Hgb: hemoglobin.

Supplemental Table 1. Prior therapies in the monotherapy cohort (n = 34).

1	None
2	Pomalidomide, momelotinib
3	None
4	Ruxolitinib, danazol
5	ESA, IV iron (previously HU, anagrelide for ET)
6	Investigational JAKi, splenectomy, ESA, investigational anti-fibrotic
7	ESA, investigational Smac-mimetic (previously HU, anagrelide for ET)
8	HU (for ET preceding MF)
9	Danazol/prednisone, pomalidomide/prednisone
10	Thalidomide/prednisone, investigational LOXL2 antibody, pomalidomide/prednisone, investigational JAKi, danazol/deferasirox
11	Pomalidomide/prednisone, momelotinib
12	HU
13	None
14	Ruxolitinib
15	None
16	Danazol
17	ESA
18	Ruxolitinib, thalidomide/prednisone
19	HU
20	Ruxolitinib, splenectomy, thalidomide/prednisone
21	Ruxolitinib, investigational Smac-mimetic
22	ESA
23	ESA
24	HU.
25	Iron, danazol, ESA
26	Pegylated interferon-alfa, iron, ESA
27	Allo SCT, ruxolitinib, investigational PI3K and PLK1 inhibitor
28	ESA
29	HU, danazol, corticosteroids
30	Investigational Smac-mimetic
31	None
32	HU (for ET preceding MF)
33	Danazol
34	Ruxolitinib, lenalidomide

Abbreviations: HU, hydroxyurea; ESA, erythroid stimulating agent; LOXL2, lysyl oxidase like-2; Smac, second mitochondrial activator of caspases; JAKi, Janus kinase inhibitor; IV, intravenous; ET, essential thrombocythemia; MF, myelofibrosis; allo SCT, allogeneic stem cell transplant; PI3K, phosphatidylinositol-3-kinase; PLK1, polo-like kinase 1.